DNA

ACADEMY FOR HEALTH AND LIFESPAN RESEARCH ANNOUNCES INDUCTION OF NEW MEMBERS

Retrieved on: 
Friday, July 19, 2024

NEW YORK, July 19, 2024 /PRNewswire/ -- The Academy for Health and Lifespan Research (AHLR, "the Academy"), the leading organization comprised of the world's most esteemed scientists dedicated to studying the mechanisms of aging and developing interventions to slow and reverse the process, today announced the induction of six new members.

Key Points: 
  • The addition of six scientists is a testament to the Academy's commitment to further its groundbreaking research, with new members who bring a wealth of expertise and experience to the organization.
  • His research focuses on the interactions between immune and metabolic systems that control inflammation and aging.
  • Her research focuses on biomarkers and pathways of metabolic health, aging, and longevity.
  • "Each of the new Academy members has a stellar academic career as a geroscientist, and more importantly, was nominated and elected because of their leadership qualities," said Nir Barzilai, MD, President of the Academy for Health and Lifespan Research.

Oligonucleotide Synthesis Market Trends and Global Forecasts 2024-2035: Current Demand Driven by Antisense Oligonucleotides, a Trend Set to Continue in the Foreseeable Future - ResearchAndMarkets.com

Retrieved on: 
Friday, July 19, 2024

The new research study consists of industry trends, detailed oligonucleotide synthesis market analysis, key market insights, market impact analysis, and oligonucleotide synthesis market forecast and opportunity analysis.

Key Points: 
  • The new research study consists of industry trends, detailed oligonucleotide synthesis market analysis, key market insights, market impact analysis, and oligonucleotide synthesis market forecast and opportunity analysis.
  • The oligonucleotide synthesis market landscape features 110+ very large, large, mid-sized and small oligonucleotide synthesis providers offering custom oligonucleotide synthesis, oligonucleotide modification and oligonucleotide purification services, which are intended for research, diagnostic and therapeutic applications.
  • Currently, North America and Europe capture around 75% of the market share of the global oligonucleotide synthesis market.
  • The opinions and insights presented in this study were Influenced by discussions conducted with multiple stakeholders in the oligonucleotide synthesis market.

Europe Clinical Laboratories Tests Market Insights 2024-2029: Increasing Outsourcing of Clinical Laboratory Testing, Rising Popularity of Digital Pathology Platforms - ResearchAndMarkets.com

Retrieved on: 
Friday, July 19, 2024

European Clinical Laboratories Tests Market is projected to reach a value of $69.1 billion in 2029 from $59.06 billion in 2023, growing at a CAGR of 2.7%

Key Points: 
  • European Clinical Laboratories Tests Market is projected to reach a value of $69.1 billion in 2029 from $59.06 billion in 2023, growing at a CAGR of 2.7%
    The Europe clinical laboratory tests market report contains exclusive data on 36 vendors.
  • Germany held the largest share, 18%, in the European clinical laboratory tests market in 2023.
  • The Europe clinical laboratory tests market by test complexity is segmented into specialty laboratory tests and routine laboratory tests.
  • The Europe clinical laboratory tests market by test type is categorized into clinical & immunochemistry, molecular diagnostics, hematology, microbiology & cytology, and toxicology.

The first published results from Juukan Gorge show 47,000 years of Aboriginal heritage was destroyed in mining blast

Retrieved on: 
Friday, July 19, 2024

Working with the Traditional Owners, we had excavated the shelter – known as Juukan 2 – in 2014, six years before its destruction.

Key Points: 
  • Working with the Traditional Owners, we had excavated the shelter – known as Juukan 2 – in 2014, six years before its destruction.
  • The results of the excavation led to last-minute efforts to stop the destruction of the site, but they were unsuccessful.
  • The full results of the excavation are published for the first time today in Quaternary Science Reviews.

Where is Juukan and what happened there?

  • The Juukan 2 rockshelter is one of the caves that make up this system.
  • As widely reported in May 2020, the Juukan 2 rockshelter was destroyed during mine expansion activities.

What is so significant about Juukan?

  • It is extremely significant both for cultural and scientific reasons.
  • For the Puutu Kunti Kurrama, Juukan is a deeply spiritual place that contains deep-time evidence of their presence and association with the landscape in their Traditional Country.
  • In terms of the scientific significance of Juukan 2, the site is one of the oldest known locations of Aboriginal settlement of Australia.
  • We don’t know what this was used for, but the ochre may indicate a ritual function.

What now?

  • Over the past two years we have removed about 150 cubic metres of rubble that was once the roof and back wall of the cave.
  • Beneath the debris we found traces of organic material, and then remnants of the cave floor.

Field-Programmable Gate Array (FPGA) Market size is set to grow by USD 4.43 billion from 2024-2028, High adoption of smartphones and tablets globally to boost the market growth, Technavio

Retrieved on: 
Thursday, July 18, 2024

FPGAs address these challenges through their re-programmability and low power consumption, making them an essential component in IoT design.

Key Points: 
  • FPGAs address these challenges through their re-programmability and low power consumption, making them an essential component in IoT design.
  • Consequently, the global FPGA market is poised for growth as IoT proliferation continues.
  • The FPGA market is experiencing significant growth in various industries, including aerospace and defense, consumer electronics, and emerging technologies.
  • In telecom, FPGAs are utilized for infotainment, cockpit applications, cloud computing, big data analytics, and hardware acceleration in 5G networks.

Chroma Medicine Appoints Renowned RNA Scientist Melissa Moore to Board of Directors

Retrieved on: 
Thursday, July 18, 2024

BOSTON, July 18, 2024 /PRNewswire/ -- Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced the appointment of Melissa J. Moore, Ph.D., to its Board of Directors.

Key Points: 
  • BOSTON, July 18, 2024 /PRNewswire/ -- Chroma Medicine , Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced the appointment of Melissa J. Moore, Ph.D., to its Board of Directors.
  • "Melissa brings decades of experience directing RNA research and drug development at leading pharma companies and in academia," said Catherine Stehman-Breen, M.D., CEO of Chroma.
  • "Her deep knowledge will benefit us as we advance our platform of highly potent and durable epigenetic editors to patients, enabling a new class of genomic medicines."
  • "Epigenetic editing is a rapidly growing field poised to transform the gene editing landscape," said Dr. Moore.

Truvius Launches To Provide Next Generation Institutional-Grade Crypto Investment Platform With $3.2M In Funding, Led by Galaxy

Retrieved on: 
Thursday, July 18, 2024

BOSTON, July 18, 2024 /PRNewswire/ -- Truvius, the company powering systematic investing for digital assets, launched today with $3.2M in funding led by Galaxy Ventures. Truvius' digital asset investment platform and products deliver institutional quality, transparent sophistication, and a fiduciary focus for institutions and high-net-worth investors. The company's funding also included participation from New Form Capital, Chainview Capital, and strategic angel investors across traditional investment management and crypto trading firms.

Key Points: 
  • Truvius' digital asset investment platform and products deliver institutional quality, transparent sophistication, and a fiduciary focus for institutions and high-net-worth investors.
  • With today's launch, institutional and high-net-worth investors can now invest in quantitative digital asset investment strategies spanning active and passive products designed by Truvius' founding team.
  • The Truvius platform delivers a cutting-edge product experience, making it easy to select and allocate to multiple digital asset investment strategies according to investors' portfolio goals.
  • Our platform uniquely empowers clients to intelligently gain this investment exposure and learn more about crypto investing through an engaging interactive experience."

Grit, Guts, and…Genetics!? Ancestry® Launches NEW Interactive DNA Compare Experience to Help Fans Discover How Their DNA Compares to More Than 15 World-Class Athletes

Retrieved on: 
Thursday, July 18, 2024

 LEHI, Utah , July 18, 2024 /PRNewswire/ -- Do you have exceptional physical power and flexibility like gymnast Gabby Douglas? Or superhuman speed like track stars Jackie Joyner-Kersee or Michael Johnson? 

Key Points: 
  • To celebrate, Ancestry® launched an interactive experience today that allows fans to compare their DNA results to world-class athletes for a limited-time at Ancestry.com/BringYourDNAGame .
  • Ancestry is also encouraging people to get into the competitive spirit by comparing their AncestryDNA athletic traits with friends and family.
  • "By enabling customers to compare their DNA traits with these world champion athletes, we're taking this to a whole new level.
  • Simply visit Ancestry.com/BringYourDNAGame , click the "Already Have Traits" link at the top, and go straight to the "Compare with World Class Athletes" experience tab.

Thiogenesis Announces Leigh Syndrome Clinical Program

Retrieved on: 
Thursday, July 18, 2024

In the agreement, the pediatric hospital will act as the Investigator in assessing Thiogenesis' lead compound, TTI-0102, in the rare mitochondrial disease Leigh syndrome.

Key Points: 
  • In the agreement, the pediatric hospital will act as the Investigator in assessing Thiogenesis' lead compound, TTI-0102, in the rare mitochondrial disease Leigh syndrome.
  • Thiogenesis has requested a pre-IND meeting with FDA, to establish the protocols for its proposed clinical trial in Leigh syndrome.
  • After the pre-IND meeting, Thiogenesis will submit an IND to FDA, with the agreed upon protocols, for a Phase 2a proof-of-concept clinical trial using TTI-0102 to treat Leigh syndrome.
  • "We also believe our proposed Phase 2a Leigh syndrome clinical trial will provide meaningful synergies with our recently announced MELAS Phase 2 clinical trial in Europe, both in the field of pediatric mitochondrial disease."

FIGS Launches Historic Campaign Honoring the Team USA Medical Team at the Olympic and Paralympic Games Paris 2024

Retrieved on: 
Thursday, July 18, 2024

FIGS (NYSE: FIGS), the leading global medical apparel brand, today announced the launch of its largest campaign to date, celebrating the Team USA Medical Team at the Olympic and Paralympic Games Paris 2024.

Key Points: 
  • FIGS (NYSE: FIGS), the leading global medical apparel brand, today announced the launch of its largest campaign to date, celebrating the Team USA Medical Team at the Olympic and Paralympic Games Paris 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240718692363/en/
    FIGS launches historic campaign honoring the Team USA Medical Team at the Olympic and Paralympic Games Paris 2024 (Photo: Business Wire)
    “Our mission at FIGS is to celebrate, empower and serve those who serve others,” said Trina Spear, CEO and Co-Founder of FIGS.
  • Additionally, FIGS will honor Team USA healthcare professionals with a “Celebration of Service” event at the Team USA House in Paris’ Palais Brongniart on August 6.
  • The FIGS x Team USA collection is now available for purchase at wearfigs.com/olympics and at the FIGS Community Hub in Los Angeles.